Drug intelligence / Profile preview

amezosvatein

Development stage: Phase 2
Lead developer: Curevo
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**Amezosvatein** is an investigational recombinant subunit vaccine being developed by Curevo Vaccine for prevention of herpes zoster. Also known as **CRV-101**, it is designed to induce protective immunity against varicella-zoster virus and uses the SLA-SE adjuvant formulation, which incorporates a Toll-like receptor 4 agonist to enhance vaccine immunogenicity. The program is being evaluated against GSK's Shingrix in adults aged 50 years and older, with development focused on achieving strong immune responses with improved tolerability.

Other names: amezosvateinCRV-101CRV101CRV 101MG-1120AMG1120AMG 1120A

Targets

TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on amezosvatein.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amezosvatein.

Explore the full profile